Agència de Salut Pública de Catalunya, Departament de Salut, Generalitat de Catalunya, Barcelona, Spain. Ciber of Epidemiology and Public Health (CIBERESP), Madrid, Spain
Departament de Salut
2024-01-25T12:34:12Z
2024-01-25T12:34:12Z
2021-03-13
Vaccination coverage; Anti-measles herd immunity; Anti-pertussis herd immunity
Cobertura de vacunación; Inmunidad colectiva contra el sarampión; Inmunidad colectiva contra la tos ferina
Cobertura de vacunació; Immunitat de grup contra el xarampió; Immunitat de grup contra la tos ferina
In 2012, the World Health Organization (WHO) established the Global Vaccine Action Plan with the objective to promote essential vaccinations in all countries and achieve at least 90% vaccination coverage for all routine vaccines by 2020. The study assessed the mean percentages of vaccination coverage in 2019 for 13 routine vaccines, vaccination coverage variation from 2015 to 2019, and herd immunity levels against measles and pertussis in 2019 in countries and regions of WHO. In 2019, the mean percentages of vaccination coverage were lower than 90% for 10 (78.9%) routine vaccines. The mean percentages of vaccination coverage also decreased from 2015 to 2019 for six (46.2%) routine vaccines. The prevalence of individuals with vaccine-induced measles immunity in the target measles vaccination population was 88.1%, and the prevalence of individuals with vaccine-induced pertussis immunity in the target pertussis vaccination population was 81.1%. Herd immunity against measles viruses with Ro = 18 was established in 63 (32.5%) countries but not established in any region. Herd immunity against pertussis agents was not established in any country and in any region of WHO. National immunization programs must be improved to achieve ≥90% vaccination coverage in all countries and regions. Likewise, it is necessary to achieve ≥95% vaccination coverage with two doses of measles vaccines and three doses of pertussis vaccines in all countries and regions.
Article
Published version
English
Xarampió - Vacunació; Tos ferina - Vacunació; Immunització; DISEASES::Virus Diseases::RNA Virus Infections::Mononegavirales Infections::Paramyxoviridae Infections::Morbillivirus Infections::Measles; DISEASES::Bacterial Infections and Mycoses::Bacterial Infections::Gram-Negative Bacterial Infections::Bordetella Infections::Whooping Cough; PHENOMENA AND PROCESSES::Immune System Phenomena::Immunity::Immunity, Herd; HEALTH CARE::Health Care Facilities, Manpower, and Services::Health Services::Preventive Health Services::Primary Prevention::Immunization::Vaccination::Vaccination Coverage; ENFERMEDADES::virosis::infecciones por virus ARN::infecciones por Mononegavirales::infecciones por Paramyxoviridae::infecciones por Morbillivirus::sarampión; ENFERMEDADES::infecciones bacterianas y micosis::infecciones bacterianas::infecciones por bacterias gramnegativas::infecciones por Bordetella::tos ferina; FENÓMENOS Y PROCESOS::fenómenos del sistema inmunitario::inmunidad::inmunidad de grupos; ATENCIÓN DE SALUD::instalaciones, servicios y personal de asistencia sanitaria::servicios de salud::servicios preventivos de salud::prevención primaria::inmunización::vacunación::cobertura de vacunación
MDPI
Vaccines;9(3)
https://doi.org/10.3390/vaccines9030256
Attribution-NonCommercial-NoDerivatives 4.0 International
http://creativecommons.org/licenses/by-nc-nd/4.0/